Atara Biotherapeutics Inc. announced it has entered into a Fourth Amendment to its Amended and Restated Commercialization Agreement with Pierre Fabre Medicament. Under the revised terms, the aggregate amount of potential milestone payments from Pierre Fabre to Atara related to FDA approval of a BLA for tab-cel has been reduced from $40 million to $31 million. Additionally, the amendment introduces a potential $15 million milestone payment from Pierre Fabre to Atara upon the achievement of a specified commercial milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-000907), on January 02, 2026, and is solely responsible for the information contained therein.